IC 31 seasonal influenza vaccine - CSL/Valneva

Drug Profile

IC 31 seasonal influenza vaccine - CSL/Valneva

Alternative Names: IC31® Flu vaccine - CSL/Valneva; Seasonal trivalent influenza vaccine (Agrippal® + IC31®) - CSL/Valneva

Latest Information Update: 18 Sep 2015

Price : $50

At a glance

  • Originator Intercell; Novartis
  • Developer CSL; Valneva
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza virus infections

Most Recent Events

  • 28 May 2013 Seasonal influenza prophylactic vaccine is still in phase I trials for Influenza virus infections in Austria
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 27 Feb 2008 Intercell completes a phase I trial in healthy volunteers in Austria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top